动态对比增强MRI早期评估肺癌化疗反应:一项概念验证研究
研究纳入22例肺癌患者,在化疗前及首程化疗开始后1周行DCE-MRI,比较反应者与非反应者的药代动力学参数(Ktrans、Kep、Ve)。13例反应者化疗后Ktrans和Ve较治疗前显著下降(p<0.05),Kep无显著变化(p>0.05);9例非反应者三项参数均无显著变化(p>0.05)。ΔKtrans预测化疗反应的最佳阈值为0.032/min,AUC 0.821、敏感度84.62%、特异度77.78%、准确率81.82%。
要点
- 化疗1周后反应者Ktrans和Ve较治疗前显著下降,非反应者三项参数均无显著变化。
- ΔKtrans在反应者中显著大于非反应者,ΔVe和ΔKep组间无统计学意义。
- ΔKtrans预测化疗反应阈值为0.032/min,AUC 0.821、敏感度84.62%、特异度77.78%。
核心结论
- DCE-MRI可能有助于评估肺癌患者化疗的早期反应,但需要更大规模、更确切的研究。
研究设计与样本
- 概念验证研究,纳入22例肺癌患者,于化疗前及首程化疗开始后1周行DCE-MRI,采用后处理平台生成药代动力学参数Ktrans、Kep和Ve,以Student t检验或Mann-Whitney U检验比较反应者与非反应者。
诊断标准与关键数值
- ΔKtrans预测肿瘤化疗反应的最佳阈值为0.032/min,对应AUC 0.821、敏感度84.62%、特异度77.78%、准确率81.82%。
临床应用与阅片要点
- 化疗前及首程化疗开始后1周行DCE-MRI,取后处理平台生成的Ktrans、Kep、Ve,以ΔKtrans 0.032/min为阈值区分反应者与非反应者;原文结论为DCE-MRI可能有助于评估早期化疗反应,但需更大规模、更确切的研究。
局限性
- 原文结论指出需要更大规模、更确切的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To evaluate the early treatment response to chemotherapy in patients with lung cancer using dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI).
MATERIALS AND METHODS: Twenty-two patients with lung cancer underwent DCE-MRI before chemotherapy and 1 week after the start of the first course of chemotherapy. Pharmacokinetic parameters (Ktrans, Kep, and Ve) derived from DCE MRI were generated using the post-processing platform. These parameters and corresponding changes were compared between responders and non-responders after treatment using Student's t or Mann-Whitney U-tests. Diagnostic efficiency of kinetic parameters in differentiating responders from non-responders after 1 week of chemotherapy was also investigated.
RESULTS: Thirteen responders after 1 week of chemotherapy had a significant decrease in Ktrans and Ve compared with the pretreatment value (p<0.05), and had no significant changes in Kep (p>0.05). Nine non-responders had no significant changes in Ktrans, Kep, and Ve compared with the pretreatment value (p>0.05). Changes in Ktrans (ΔKtrans) were significantly larger in responders than that in non-responders (p<0.05). Changes in Ve and Kep (ΔVe andΔKep) were without statistical significance after treatment between responders and non-responders (p>0.05). The cut-off value of ΔKtrans in best predicting tumour's chemotherapeutic response was 0.032/min and the corresponding AUC (area under the curve), sensitivity, specificity, and accuracy were 0.821, 84.62%, 77.78%, and 81.82%, respectively.
CONCLUSION: DCE MRI may be useful for evaluating the early response to chemotherapy in patients with lung cancer, but larger, more definitive studies are needed.
引用
- Xu J, Mei L, Liu L, et al. Early assessment of response to chemotherapy in lung cancer using dynamic contrast-enhanced MRI: a proof-of-concept study. Clin Radiol. 2018. PMID: 29571650. doi:10.1016/j.crad.2018.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。